Compare KELYA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYA | BCYC |
|---|---|---|
| Founded | 1946 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.1M | 291.8M |
| IPO Year | 1994 | 2019 |
| Metric | KELYA | BCYC |
|---|---|---|
| Price | $16.09 | $4.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $15.00 | $13.90 |
| AVG Volume (30 Days) | ★ 350.9K | 309.6K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $5,355,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | $107.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.98 | $3.75 |
| 52 Week High | $17.75 | $9.16 |
| Indicator | KELYA | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 43.84 |
| Support Level | $8.48 | $3.94 |
| Resistance Level | $16.20 | $4.21 |
| Average True Range (ATR) | 0.71 | 0.14 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 43.17 | 41.94 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.